MCID: VRR004
MIFTS: 48

Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 15 17
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Carcinoma, Verrucous 44
Carcinoma Verrucous 54
Warty Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3737
MeSH 44 D018289
NCIt 50 C3781
SNOMED-CT 67 89906000
UMLS 70 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to esophagus verrucous carcinoma and squamous cell papilloma. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Carboplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and skin, and related phenotypes are cellular and immune system

Wikipedia : 73 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 esophagus verrucous carcinoma 32.2 TP53 MDM2 EGFR CDKN2A CCND1
2 squamous cell papilloma 31.5 TP53 CDKN2A
3 keratosis 30.7 TP53 KRT5 KRT10 CDKN2A
4 penile benign neoplasm 30.7 TP53 CDKN2A
5 vulvar intraepithelial neoplasia 30.6 TP53 CDKN2A
6 human papillomavirus infectious disease 30.6 TP53 CDKN2A
7 suppressor of tumorigenicity 3 30.5 TP53 CDKN2A
8 papilloma 30.4 TP53 PTEN KRT5 KRT10 EGFR CDKN2A
9 actinic cheilitis 30.3 TP53 MDM2
10 squamous cell carcinoma 30.3 TP53 PTEN MMP9 EGFR CDKN2A CCND1
11 anus cancer 30.3 TP53 EGFR CDKN2A
12 eccrine acrospiroma 30.2 KRT5 KRT10
13 malignant peritoneal mesothelioma 30.2 EGFR CDKN2A
14 keratoacanthoma 30.2 TP53 KRT10 EGFR
15 papillary squamous carcinoma 30.2 KRT5 EGFR CDKN2A
16 anal squamous cell carcinoma 30.1 TP53 MDM2 CDKN2A
17 cheilitis 30.1 TP53 MMP9 MDM2
18 vulva squamous cell carcinoma 30.1 TP53 EGFR CDKN2A
19 in situ carcinoma 30.1 TP53 PTEN KRT5 EGFR CDKN2A CCND1
20 gastric squamous cell carcinoma 30.1 KRT5 KRT10
21 middle ear carcinoma 30.0 MMP9 KRT5 CDKN2A
22 keratosis, seborrheic 30.0 TP53 KRT5 KRT10 CDKN2A
23 inverted papilloma 30.0 TP53 KRT5 EGFR CDKN2A
24 peripheral t-cell lymphoma 30.0 TP53 PTEN CCND1
25 penile cancer 29.9 TP53 PTEN EGFR CDKN2A CCND1
26 laryngeal squamous cell carcinoma 29.9 TP53 PTEN EGFR CDKN2A CCND1
27 vulva cancer 29.9 TP53 PTEN EGFR CDKN2A
28 barrett esophagus 29.9 TP53 CDKN2A CCND1
29 cowden syndrome 1 29.8 TP53 PTEN EGFR
30 gastroesophageal reflux 29.8 TP53 MDM2 EGFR CCND1
31 colon adenocarcinoma 29.8 TP53 PTEN EGFR CCND1
32 adenosquamous carcinoma 29.7 TP53 PTEN KRT5 EGFR CDKN2A
33 endometrial adenocarcinoma 29.7 TP53 PTEN EGFR CDKN2A CCND1
34 retinoblastoma 29.7 TP53 MDM2 CDKN2A CDK6 CCND1
35 oral squamous cell carcinoma 29.7 TP53 MMP9 MIR31 MIR195 EGFR CDKN2A
36 meningioma, familial 29.7 TP53 PTEN MSN EGFR CDKN2A
37 oropharynx cancer 29.6 TP53 KRT5 EGFR CDKN2A CCND1
38 b-cell lymphoma 29.4 TP53 MDM2 CDKN2A CDK6 CCND1
39 oral cancer 29.3 TP53 MMP9 MIR31 MDM2 EGFR CDKN2A
40 esophageal disease 29.2 TP53 MIR31 MIR125A EGFR CCND1
41 lymphoma 29.2 TP53 MDM2 EGFR CDKN2A CDK6 CCND1
42 skin disease 28.7 TP53 MIR31 MIR125A KRT5 KRT10 EGFR
43 larynx cancer 28.7 TP53 MIR31 MIR195 MIR125A EGFR CDKN2A
44 adenocarcinoma 28.7 TP53 PTEN MMP9 MDM2 ERBB3 EGFR
45 basal cell carcinoma 28.7 TP53 PTEN MMP9 MDM2 KRT5 KRT10
46 skin carcinoma 28.0 TP53 PTEN MMP9 MIR31 MDM2 KRT5
47 squamous cell carcinoma, head and neck 28.0 TP53 PTEN MMP9 MIR31 MIR195 ERBB3
48 esophageal cancer 27.9 TP53 PTEN MMP9 MIR31 MDM2 ERBB3
49 endometrial cancer 27.5 TP53 PTEN MMP9 MIR31 MDM2 ERBB3
50 larynx verrucous carcinoma 11.4

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

MGI Mouse Phenotypes related to Verrucous Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
2 immune system MP:0005387 10.26 CCND1 CDK6 CDKN2A EGFR ERBB3 KRT5
3 digestive/alimentary MP:0005381 10.21 CCND1 CDKN2A EGFR ERBB3 KRT5 LRIG1
4 integument MP:0010771 10.16 CCND1 CDKN2A EGFR ERBB3 KRT5 LRIG1
5 endocrine/exocrine gland MP:0005379 10.15 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
6 neoplasm MP:0002006 10.07 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
7 nervous system MP:0003631 10.02 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
8 muscle MP:0005369 10.01 CDK6 CDKN2A EGFR ERBB3 MDM2 MMP9
9 limbs/digits/tail MP:0005371 9.98 EGFR KRT5 LRIG1 MDM2 MMP9 PTEN
10 normal MP:0002873 9.86 CCND1 EGFR ERBB3 LRIG1 MDM2 MSN
11 pigmentation MP:0001186 9.63 CDKN2A EGFR ERBB3 MDM2 PTEN TP53
12 respiratory system MP:0005388 9.56 CCND1 CDKN2A EGFR ERBB3 MMP9 MSN
13 vision/eye MP:0005391 9.28 CCND1 CDK6 CDKN2A EGFR LRIG1 MMP9

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
3
Fluorouracil Approved Phase 3 51-21-8 3385
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5 Angiogenesis Inhibitors Phase 3
6 Tubulin Modulators Phase 3
7 Antimitotic Agents Phase 3
8 Mitogens Phase 3
9 Endothelial Growth Factors Phase 3
10 Immunoglobulin G Phase 3
11 Antimetabolites Phase 3
12
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
13 Raspberry Approved Phase 1, Phase 2
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
17
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
18
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
19
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
20
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
21
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
22
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
23
Trioxsalen Approved Phase 2 3902-71-4 5585
24
Saracatinib Investigational Phase 2 379231-04-6
25
Cediranib Investigational Phase 2 288383-20-0 9933475
26
Maleic acid Experimental Phase 2 110-16-7 444266
27
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
28 Protein Kinase Inhibitors Phase 2
29 Antioxidants Phase 2
30
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
31 Anti-Infective Agents Phase 2
32 Anti-Bacterial Agents Phase 2
33 Antibiotics, Antitubercular Phase 2
34 Antifungal Agents Phase 2
35 Epothilones Phase 2
36 Epothilone B Phase 2
37 Lactams Phase 2
38 Soy Bean Phase 2
39 topoisomerase I inhibitors Phase 2
40 Proteasome Inhibitors Phase 2
41 Respiratory System Agents Phase 2
42 Antidotes Phase 2
43 Protective Agents Phase 2
44 Expectorants Phase 2
45 Antiviral Agents Phase 2
46 N-monoacetylcystine Phase 2
47 Photosensitizing Agents Phase 2
48 Dermatologic Agents Phase 2
49 Dihematoporphyrin Ether Phase 2
50 Ether Phase 2

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
2 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
3 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
4 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
5 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
6 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
7 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
8 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
9 Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck Completed NCT01414426 Phase 2 vandetanib
10 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
11 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
12 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
13 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
14 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
15 A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma Completed NCT02007200 Phase 2 Soy Isoflavones
16 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
17 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
18 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
19 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
20 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
21 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
22 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
23 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
24 A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Terminated NCT01192815 Phase 2 erlotinib hydrochloride
25 Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
26 A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN) Terminated NCT02196168 Phase 2 Cisplatin;WEE1 Inhibitor AZD1775
27 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
28 A Randomized Multicenter Phase II Study Using HPPH With PDT Versus Standard of Care Surgery for Patients With T1/T2 Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02119728 Phase 2 HPPH
29 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
30 Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
31 Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study Completed NCT01254617 Phase 1 Lenalidomide
32 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
33 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
34 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
35 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
36 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
37 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
38 A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
39 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
40 Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. Active, not recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
41 A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer Terminated NCT00906360 Phase 1 sunitinib malate
42 A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC) Terminated NCT01283178 Phase 1 cisplatin
43 A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) Terminated NCT01528137 Phase 1
44 A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection Terminated NCT01249443 Phase 1 vorinostat;carboplatin;paclitaxel
45 A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
46 A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
47 L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study Completed NCT01155609
48 The Role of Direct Visual Fluorescence in Oral Examination Completed NCT01816841
49 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
50 Pilot Long-Term Oral Dose of Freeze-Dried Black Raspberries in Post-Surgical Appalachian Oral Cancer Completed NCT01504932

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

40
Breast, Cervix, Skin, Lung, Tongue, Bone, Thyroid

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 1240)
# Title Authors PMID Year
1
Shifts in cellular localization of moesin in normal oral epithelium, oral epithelial dysplasia, verrucous carcinoma and oral squamous cell carcinoma. 61 54
12787041 2003
2
Expression of moesin and its associated molecule CD44 in epithelial skin tumors. 61 54
9696288 1998
3
Incidental secondary findings in hemorrhoidectomy specimens: a 16-year experience from a single academic center. 61
33245989 2021
4
Cutaneous horn overlying verrucous carcinoma on face and its dermoscopic characterization. 61
33666037 2021
5
Rare combination of verrucous carcinoma and syringocystadenoma papilliferum in anterior perineal sinus: recognizing the absence of normality. 61
33792154 2021
6
Photodynamic therapy with acitretin for treatment of penile verrucous carcinoma. 61
33022419 2021
7
Oral Cancer: Raising Awareness of the Importance of Suspicion in Early Detection. 61
33722122 2021
8
Clinical Challenges in Resection and Reconstruction of a Verrucous Carcinoma of the Right Calcaneus With a Medial Plantar Artery Perforator Flap: A Case Report. 61
33728136 2021
9
Pseudoepitheliomatous keratotic and micaceous balanitis: low-risk human papilloma virus detection in two further cases. 61
33342358 2021
10
Verruciform Xanthoma of the Ventral Surface of the Tongue: A Rare Case Report and Literature Review. 61
33654692 2021
11
Optimal treatment for penile verrucous carcinoma: a systematic literature review. 61
33514369 2021
12
Clinicopathological Features Associated with Fluorescence Alteration: Analysis of 108 Oral Malignant and Potentially Malignant Lesions. 61
33332238 2021
13
Scrotal Verrucous Carcinoma: An Exceptional Localization of a Rare Tumor. 61
33688353 2021
14
Oral verrucous carcinoma manifesting as proliferative verrucous leukoplakia. 61
33451921 2021
15
Löwenstein-Buschke: Clinicopathologic Analysis of 78 Cases of Large and Giant Condyloma Acuminata of the Anus. 61
33021736 2021
16
Malignant transformation of oral proliferative verrucous leukoplakia: a series of 48 patients with suggestions for management. 61
32586723 2021
17
Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva. 61
33323855 2020
18
Buschke-Loewenstein Tumor: A Case Report and Advocacy for Human Papillomavirus Vaccination. 61
33154856 2020
19
Nucleolar organizer regions in human oral verrucous carcinoma and adjacent lining epithelium. 61
32124655 2020
20
Verrucous carcinoma of the esophagus - a case report and literature review. 61
33036050 2020
21
Differentiated exophytic vulvar intraepithelial lesion: Clinicopathologic and molecular analysis documenting its relationship with verrucous carcinoma of the vulva. 61
32427961 2020
22
Oral retinoid, acitretin, is effective in the management of resistant recurrent vulval verrucous carcinoma: A case report. 61
32755050 2020
23
Mandible extensive intra osseous destructive lesion, a diagnostic challenge. 61
31610243 2020
24
Incidental Finding of Oral White Lesions Due to Tobacco Chewing - A Case Report. 61
33708602 2020
25
Evaluation of the presence of myofibroblasts and matrix metalloproteinase 1 expression in the stroma of oral verrucous hyperplasia and verrucous carcinoma. 61
32769324 2020
26
Differential Expression of EZH2 and H3K27me3 in Oral Verrucous Carcinoma and Oral Verrucous Hyperplasia. 61
32720035 2020
27
Complex microsurgical perineal reconstruction after resection of a giant verrucous carcinoma associated with anal fistulas in Crohn's disease-a unique case report. 61
32179992 2020
28
Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data. 61
32307745 2020
29
Importance of Ki-67 Labeling in Oral Leukoplakia with Features of Dysplasia and Carcinomatous Transformation: An Observational Study over 4 Years. 61
33365288 2020
30
Verrucous hyperplasia and verrucous carcinoma in head and neck: use and benefit of methotrexate. 61
32279645 2020
31
Verrucous carcinoma of the upper lip: An exuberant presentation in a patient with other synchronous lesions. 61
31274469 2020
32
Inter-observer Variability in the Diagnosis of Proliferative Verrucous Leukoplakia: Clinical Implications for Oral and Maxillofacial Surgeon Understanding: A Collaborative Pilot Study. 61
30972634 2020
33
Histopathological determinants of autofluorescence patterns in oral carcinoma. 61
32045089 2020
34
Verrucous carcinoma of the esophagus: a case report and literature review. 61
32030515 2020
35
Epithelial-myoepithelial carcinoma on lower lip and microinvasive verrucous carcinoma in vocal cord: Case report. 61
32259043 2020
36
Syringocystadenoma papilliferum associated with verrucous carcinoma of the skin in the same lesion: Report of four cases. 61
31449665 2020
37
Verrucous Carcinoma in a Giant Cutaneous Horn: A Case Report and Literature Review. 61
32082671 2020
38
Non-HPV-related verrucous carcinoma of the endometrium: report of one case and review of literature. 61
32661482 2020
39
Head and neck verrucous carcinoma: A population-based analysis of incidence, treatment, and prognosis. 61
31914052 2020
40
Histopathological Assessment for Esophageal Squamous Cell Carcinoma. 61
32056166 2020
41
Patterns of Care and Outcomes in Verrucous Carcinoma of the Larynx Treated in the Modern Era. 61
32850375 2020
42
[To the question of proliferative verrucous leukoplakia malignant potential]. 61
32593261 2020
43
A Case Report of an Early Response to Definitive Chemoradiation for Esophageal Carcinoma Cuniculatum. 61
32373377 2020
44
[Oral Floor Reconstruction with Digastric Muscle Bipedicle Flap for Advanced Tongue Cancer in Very Elderly Patients-Report of Two Cases]. 61
32156873 2019
45
Clinicopathologic analysis of verrucous hyperplasia, verrucous carcinoma and squamous cell carcinoma as part of the clinicopathologic spectrum of oral proliferative verrucous leukoplakia: A literature review and analysis. 61
31630872 2019
46
Lichenoid Characteristics in Premalignant Verrucous Lesions and Verrucous Carcinoma of the Oral Cavity. 61
30671763 2019
47
Expanded Expression of Toll-Like Receptor 2 in Proliferative Verrucous Leukoplakia. 61
30888638 2019
48
Nonhealing Wounds with Verrucous Presentation in the Neuropathic Patient: A Report of Two Cases. 61
31755775 2019
49
Verrucous Carcinoma of the Nail Bed: A New Case. 61
31799266 2019
50
Is primary radiotherapy an acceptable treatment modality for verrucous carcinoma of the larynx? 61
30950508 2019

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 TP53 PTEN MDM2 ERBB3 EGFR CDKN2A
2
Show member pathways
12.95 TP53 PTEN MDM2 ERBB3 EGFR CDK6
3
Show member pathways
12.94 TP53 MDM2 EGFR CDKN2A CDK6 CCND1
4
Show member pathways
12.81 TP53 PTEN ERBB3 EGFR CCND1
5
Show member pathways
12.81 TP53 MSN MDM2 CDK6 CCND1
6
Show member pathways
12.74 TP53 PTEN EGFR CDKN2A CDK6 CCND1
7 12.73 TP53 PTEN MMP9 MDM2 EGFR CDKN2A
8
Show member pathways
12.72 TP53 PTEN MDM2 ERBB3 EGFR
9
Show member pathways
12.66 TP53 PTEN MMP9 MDM2 EGFR CDKN2A
10
Show member pathways
12.57 TP53 MDM2 CDKN2A CDK6 CCND1
11 12.51 TP53 MDM2 CDKN2A CDK6 CCND1
12
Show member pathways
12.49 TP53 PTEN ERBB3 EGFR
13
Show member pathways
12.45 TP53 PTEN MDM2 ERBB3 EGFR CCND1
14
Show member pathways
12.44 TP53 MDM2 ERBB3 EGFR
15
Show member pathways
12.41 TP53 PTEN MMP9 MDM2 ERBB3 EGFR
16
Show member pathways
12.4 TP53 PTEN MDM2 CCND1
17
Show member pathways
12.35 TP53 CDKN2A CDK6 CCND1
18 12.35 TP53 MDM2 CDKN2A CDK6 CCND1
19
Show member pathways
12.34 TP53 PTEN MDM2 EGFR
20 12.33 TP53 PTEN CDKN2A CCND1
21
Show member pathways
12.3 TP53 PTEN MDM2 EGFR CCND1
22
Show member pathways
12.3 TP53 PTEN MDM2 CDKN2A CDK6 CCND1
23 12.28 TP53 MDM2 CDKN2A CDK6 CCND1
24
Show member pathways
12.25 TP53 PTEN MDM2 CCND1
25 12.19 TP53 MMP9 EGFR CCND1
26
Show member pathways
12.19 TP53 PTEN MDM2 ERBB3 EGFR CCND1
27 12.18 TP53 MSN MMP9 MDM2 ERBB3 EGFR
28 12.13 TP53 PTEN MDM2 EGFR CCND1
29
Show member pathways
12.1 PTEN MDM2 EGFR CCND1
30 12.1 TP53 PTEN MDM2 CDKN2A CDK6 CCND1
31 12.08 TP53 PTEN MDM2 EGFR
32 12.03 TP53 MMP9 EGFR CCND1
33
Show member pathways
11.97 MDM2 LRIG1 ERBB3 EGFR
34 11.96 TP53 MMP9 CCND1
35 11.96 TP53 PTEN MDM2 CDKN2A
36 11.95 TP53 PTEN MDM2 CDKN2A CCND1
37
Show member pathways
11.93 CDKN2A CDK6 CCND1
38 11.89 TP53 PTEN MMP9 MIR31 MIR195 MIR125A
39 11.88 TP53 PTEN CDK6 CCND1
40 11.87 PTEN MDM2 EGFR CCND1
41 11.85 TP53 MDM2 CDK6 CCND1
42 11.81 TP53 MDM2 KRT5
43
Show member pathways
11.75 TP53 MDM2 CDKN2A
44 11.75 TP53 MDM2 CDKN2A
45 11.73 TP53 PTEN EGFR
46 11.69 MSN MMP9 EGFR
47 11.65 MSN MMP9 EGFR
48 11.6 TP53 MDM2 CDKN2A
49 11.6 TP53 MMP9 MDM2 EGFR CDKN2A CCND1
50
Show member pathways
11.59 MMP9 EGFR CCND1

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MSN MMP9 MIR31 MIR125A LRIG1 KRT10

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 PTEN MDM2 ERBB3 EGFR CCND1
2 negative regulation of apoptotic process GO:0043066 9.95 TP53 PTEN MMP9 MDM2 EGFR
3 response to drug GO:0042493 9.88 TP53 PTEN MDM2 CCND1
4 negative regulation of cell proliferation GO:0008285 9.85 TP53 PTEN MIR195 CDKN2A CDK6
5 positive regulation of apoptotic process GO:0043065 9.83 TP53 PTEN MMP9 MIR195 CDKN2A
6 heart development GO:0007507 9.81 TP53 PTEN MDM2 ERBB3
7 response to estradiol GO:0032355 9.79 PTEN EGFR CCND1
8 G1/S transition of mitotic cell cycle GO:0000082 9.77 CDKN2A CDK6 CCND1
9 regulation of cell cycle GO:0051726 9.71 TP53 PTEN CDK6 CCND1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.65 PTEN CDKN2A CDK6
11 replicative senescence GO:0090399 9.62 TP53 CDKN2A
12 cardiac septum morphogenesis GO:0060411 9.61 TP53 MDM2
13 dentate gyrus development GO:0021542 9.61 PTEN CDK6
14 response to magnesium ion GO:0032026 9.59 MDM2 CCND1
15 amyloid fibril formation GO:1990000 9.58 MDM2 CDKN2A
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 TP53 EGFR
17 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR31 MIR125A
18 mitotic G1 DNA damage checkpoint GO:0031571 9.52 TP53 CCND1
19 cellular response to UV-C GO:0071494 9.49 TP53 MDM2
20 negative regulation of mitotic cell cycle GO:0045930 9.43 TP53 MIR195 EGFR
21 cellular response to actinomycin D GO:0072717 9.37 TP53 MDM2
22 regulation of cell motility GO:2000145 9.33 ERBB3 EGFR CDK6
23 response to UV-A GO:0070141 9.32 EGFR CCND1
24 positive regulation of gene expression GO:0010628 9.17 TP53 PTEN MSN MIR125A MDM2 ERBB3
25 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.13 TP53 PTEN MIR195

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.83 ERBB3 EGFR CDKN2A CDK6 CCND1
2 ubiquitin protein ligase binding GO:0031625 9.71 TP53 MDM2 ERBB3 EGFR
3 mRNA 3'-UTR binding GO:0003730 9.56 TP53 MIR31 MIR195 MIR125A
4 p53 binding GO:0002039 9.5 TP53 MDM2 CDKN2A
5 SUMO transferase activity GO:0019789 9.46 MDM2 CDKN2A
6 protein kinase binding GO:0019901 9.43 TP53 PTEN MSN EGFR CDKN2A CCND1
7 MDM2/MDM4 family protein binding GO:0097371 9.37 TP53 CDKN2A
8 disordered domain specific binding GO:0097718 9.33 TP53 MDM2 CDKN2A
9 enzyme binding GO:0019899 9.1 TP53 PTEN MSN MDM2 EGFR CCND1

Sources for Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....